SMSteven de Maat

Steven de Maat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven de Maat has a total of 127 co-authors. Here are the top co-authors by number of shared publications:

  • Coen Maas

    Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

    26 shared publications
  • Arjan D. Barendrecht

    Central Diagnostic Laboratory Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

    7 shared publications
  • Claudia Tersteeg

    Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium

    6 shared publications
  • Gerard Pasterkamp

    Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

    6 shared publications
  • Wariya Sanrattana

    Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

    6 shared publications
  • Chantal C. Clark

    University Medical Center Utrecht, Utrecht University, Center for Benign Hematology, Thrombosis and Hemostasis- Van Creveldkliniek, Utrecht, the Netherlands; Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, the Netherlands

    5 shared publications

Latest Publications

  • Open Access

    Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis

    by Hinde El Otmani, Rowan Frunt, Simone Smits, Arjan D. Barendrecht, Steven de Maat, Rob Fijnheer, Peter J. Lenting, Claudia Tersteeg

    Von Willebrand factor (VWF) is an essential contributor to microvascular thrombosis. Physiological cleavage by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) limits its prothrombotic properties, explaining why ADAMTS13 deficiency leads to attacks of microthrombosis in patients with thrombotic thrombocytopenic purpura (TTP). We previously reported that plasminogen activation takes place during TTP attacks in these patients. Furthermore, stimulation of plasminogen activation attenuates pathogenesis in preclinical TTP models in vivo. This suggests that plasmin is an endogenous regulator of VWF thrombogenicity, in particular when ADAMTS13 falls short to prevent microvascular occlusions. VWF cleavage by plasmin is biochemically distinct from cleavage by ADAMTS13. We hypothesized that plasmin-cleaved VWF (cVWF) holds value as a biomarker of microvascular thrombosis. Here, we describe the development of a variable domain of heavy-chain-only antibody (VHH)-based bioassay that can distinguish cVWF from intact and ADAMTS13-cleaved VWF in plasma. We validate this assay by tracking cVWF release during degradation of microthombi in vitro. We demonstrate that endogenous cVWF formation takes place in patients with TTP during acute attacks of thrombotic microangiopathy but not in those in remission. Finally, we show that therapeutic plasminogen activation in a mouse model of TTP amplifies cVWF formation, which is accompanied by VWF clearance. Our combined findings indicate that cVWF is released from microthrombi in the context of microvascular occlusion.


  • VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models

    by Marc V. A. van Moorsel, Steven de Maat, Kristof Vercruysse, Esther M. van Leeuwen, Charlène Jacqmarcq, Thomas Bonnard, Denis Vivien, H. Bart van der Worp, Rick M. Dijkhuizen, Coen Maas

    Recombinant human tissue plasminogen activator (rh-tPA) is an important thrombolytic agent for treatment of acute ischemic stroke. It requires fibrin binding for plasminogen activation. In contrast, Microlyse, a novel thrombolytic agent, requires von Willebrand factor (VWF) binding for plasminogen activation. We compared rh-tPA with Microlyse, administered 20 minutes after inducing thrombosis, in 2 randomized blinded acute ischemic stroke mouse models. Thrombosis was induced in the middle cerebral artery with different experimental triggers. Where thrombin infusion generates fibrin-rich thrombi, topical FeCl3 application generates platelet-rich thrombi. In the fibrin-rich model, both rh-tPA and Microlyse increased cortical reperfusion (determined by laser speckle imaging) 10 minutes after therapy administration (35.8 ± 17.1%; P = .001 39.3 ± 13.1%; P < .0001; 15.6 ± 7.5%, respectively, vs vehicle). In addition, both thrombolytic agents reduced cerebral lesion volume (determined by magnetic resonance imaging) after 24 hours (18.9 ± 11.2 mm3; P = .033; 16.1 ± 13.9 mm3; P = .018; 26.6 ± 5.6 mm3, respectively, vs vehicle). In the platelet-rich model, neither rh-tPA nor Microlyse increased cortical reperfusion 10 minutes after therapy (7.6 ± 8.8%; P = .216; 16.3 ± 13.9%; P = .151; 10.1 ± 7.9%, respectively, vs vehicle). However, Microlyse, but not rh-tPA, decreased cerebral lesion volumes (13.9 ± 11.4 mm3; P < .001; 23.6 ± 11.1 mm3; P = .188; 30.3 ± 10.9 mm3, respectively, vs vehicle). These findings support broad applicability of Microlyse in ischemic stroke, irrespective of the thrombus composition.


  • Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis

    by Steven de Maat, Chantal C. Clark, Arjan D. Barendrecht, Simone Smits, Nadine D. van Kleef, Hinde El Otmani, Manon Waning, Marc Vincent Adriaan van Moorsel, Michael Szardenings, Nicolas Delaroque, et al.

    Thrombotic microangiopathies are hallmarked by attacks of disseminated microvascular thrombosis. In thrombotic thrombocytopenic purpura (TTP), this is caused by a rise in thrombogenic ultra-large von Willebrand factor (VWF) multimers because of ADAMTS13 deficiency. We previously reported that systemic plasminogen activation is therapeutic in a TTP mouse model. In contrast to its natural activators (ie, tissue plasminogen activator and urokinase plasminogen activator [uPA]), plasminogen can directly bind to VWF. For optimal efficacy and safety, we aimed to focus and accelerate plasminogen activation at sites of microvascular occlusion. We here describe the development and characterization of Microlyse, a fusion protein consisting of a high-affinity VHH targeting the CT/CK domain of VWF and the protease domain of uPA, for localized plasminogen activation on microthrombi. Microlyse triggers targeted destruction of platelet-VWF complexes by plasmin on activated endothelial cells and in agglutination studies. At equal molar concentrations, Microlyse degrades microthrombi sevenfold more rapidly than blockade of platelet-VWF interactions with a bivalent humanized VHH (caplacizumab*). Finally, Microlyse attenuates thrombocytopenia and tissue damage (reflected by increased plasma lactate dehydrogenase activity, as well as PAI-1 and fibrinogen levels) more efficiently than caplacizumab* in an ADAMTS13−/− mouse model of TTP, without affecting hemostasis in a tail-clip bleeding model. These findings show that targeted thrombolysis of VWF by Microlyse is an effective strategy for the treatment of TTP and might hold value for other forms of VWF-driven thrombotic disease.


  • A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs

    by Wariya Sanrattana, Thibaud Sefiane, Simone Smits, Nadine D. van Kleef, Marcel H. Fens, Peter J. Lenting, Coen Maas, Steven de Maat

    Significance: Serine protease inhibitors (SERPINs) regulate vital physiological processes. Considerable research effort has gone into the development of SERPINs as therapeutic agents. One of the development goals is SERPIN modification for improved specificity toward desired target(s). The specificity and potency of SERPINs can be altered by changing their reactive center loop (RCL). Currently, predicting these properties of a RCL sequence is almost impossible. By characterizing 160 α1-antitrypsin RCL variants with single–amino acid substitutions, we developed a SERPIN RCL-based platform that predicts the inhibitory behavior for SERPIN variants with compounded RCL mutations. This platform was applied to design a next-generation SERPIN against activated protein C and provides evidence for its value in the treatment of hemophilia A.


  • Open Access

    Targeted SERPIN (TaSER): A dual‐action antithrombotic agent that targets platelets for SERPIN delivery

    by Wariya Sanrattana, Simone Smits, Arjan D. Barendrecht, Nadine D. van Kleef, Hinde El Otmani, Minka Zivkovic, Mark Roest, Thomas Renné, Chantal C. Clark, Steven de Maat, et al.


  • Open Access

    Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema

    by Steven de Maat, Kusumam Joseph, Coen Maas, Allen P. Kaplan

    The plasma contact system is the initiator of the intrinsic pathway of coagulation and the main producer of the inflammatory peptide bradykinin. When plasma is exposed to a negatively charged surface the two enzymes factor XII (FXII) and plasma prekallikrein (PK) bind to the surface alongside the co-factor high molecular weight kininogen (HK), where PK is non-covalently bound to. Here, FXII and PK undergo a reciprocal activation feedback loop that leads to full contact system activity in a matter of seconds. Although naturally occurring negatively charged surfaces have shown to be involved in the role of the contact system in thrombosis, such surfaces are elusive in the pathogenesis of bradykinin-driven hereditary angioedema (HAE). In this review, we will explore the molecular mechanisms behind contact system activation, their assembly on the endothelial surface, and their role in the HAE pathophysiology.


  • Open Access

    Therapeutic SERPINs: Improving on Nature

    by Coen Maas, Steven de Maat

    Serine proteases drive important physiological processes such as coagulation, fibrinolysis, inflammation and angiogenesis. These proteases are controlled by serine protease inhibitors (SERPINs) that neutralize their activity. Currently, over 1,500 SERPINs are known in nature, but only 37 SERPINs are found in humans. Thirty of these are functional protease inhibitors. The inhibitory potential of SERPINs is in perfect balance with the proteolytic activities of its targets to enable physiological protease activity. Hence, SERPIN deficiency (either qualitative or quantitative) can lead to disease. Several SERPIN resupplementation strategies have been developed to treat SERPIN deficiencies, including concentrates derived from plasma and recombinant SERPINs. SERPINs usually inhibit multiple proteases, but only in their active state. Over the past decades, considerable insights have been acquired in the identification of SERPIN biological functions, their inhibitory mechanisms and specificity determinants. This paves the way for the development of therapeutic SERPINs. Through rational design, the inhibitory properties (selectivity and inhibitory potential) of SERPINs can be reformed and optimized. This review explores the current state of SERPIN engineering with a focus on reactive center loop modifications and backbone stabilization. We will discuss the lessons learned from these recombinant SERPINs and explore novel techniques and strategies that will be essential for the creation and application of the future generation of therapeutic SERPINs.


  • Detecting oral kallikrein-targeting therapy through triggered contact activation: A phase I study

    by Zonne L.M. Hofman, Chantal C. Clark, C. Erik. Hack, Steven de Maat, Coen Maas


  • Open Access

    A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation

    by Zonne L. M. Hofman, Chantal C. Clark, Wariya Sanrattana, Aziz Nosairi, Naomi M. J. Parr, Minka Živkovic, Karoline Krause, Niklas A. Mahnke, Jörg Scheffel, C. Erik Hack, et al.


  • Open Access

    Heparin Forms Polymers with Cell-free DNA Which Elongate Under Shear in Flowing Blood

    by Joost C. de Vries, Arjan D. Barendrecht, Chantal C. Clark, Rolf T. Urbanus, Peter Boross, Steven de Maat, Coen Maas

    Heparin is a widely used anticoagulant which inhibits factor Xa and thrombin through potentiation of antithrombin. We recently identified that the nucleic acid stain SYTOX reacts with platelet polyphosphate due to molecular similarities, some of which are shared by heparin. We attempted to study heparin in flowing blood by live-cell fluorescence microscopy, using SYTOX for heparin visualisation. Immunostaining was performed with monoclonal antibodies directed against various heparin-binding proteins. In addition, we studied modulation of heparin activity in coagulation assays, as well its effects on fibrin formation under flow in recalcified whole blood. We found that SYTOX-positive polymers appear in heparinised blood under flow. These polymers typically associate with platelet aggregates and their length (reversibly) increases with shear rate. Immunostaining revealed that of the heparin-binding proteins assessed, they only contain histones. In coagulation assays and flow studies on fibrin formation, we found that addition of exogenous histones reverses the anticoagulant effects of heparin. Furthermore, the polymers do not appear in the presence of DNase I, heparinase I/III, or the heparin antidote protamine. These findings suggest that heparin forms polymeric complexes with cell-free DNA in whole blood through a currently unidentified mechanism.